ECSP024392A - GLUCAGON TYPE-1 PEPTIDE ANALOGS - Google Patents
GLUCAGON TYPE-1 PEPTIDE ANALOGSInfo
- Publication number
- ECSP024392A ECSP024392A ECSP024392A ECSP024392A EC SP024392 A ECSP024392 A EC SP024392A EC SP024392 A ECSP024392 A EC SP024392A EC SP024392 A ECSP024392 A EC SP024392A
- Authority
- EC
- Ecuador
- Prior art keywords
- glp
- glu
- asp
- ala
- lys
- Prior art date
Links
- 102000051325 Glucagon Human genes 0.000 title 1
- 108060003199 Glucagon Proteins 0.000 title 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
- 229960004666 glucagon Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 3
- -1 GLP-1 compound Chemical class 0.000 abstract 3
- XVOYSCVBGLVSOL-UHFFFAOYSA-N L-cysteine sulfonic acid Natural products OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 abstract 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 abstract 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 abstract 1
- 108010077515 glycylproline Proteins 0.000 abstract 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto GLP-1 que comprende la secuencia de aminoácidos de fórmula 1 (SEQ ID No. 1) His-Xaa8-Glu-Gly-Xaa11-Xaa12-Thr-Ser-asp-Xaa16-Ser-Ser-Tyr-Leu-Glu-Xaa22-Xaa23-Xaa24-Ala-Xaa27-Phe-Ile-Ala-Xaa31-Leu-Xaa33-Xaa34-Xaa35-Xaa36-R . Fórmula I (SEQ ID No:1) en la que: Xaa8 es: Gly, Ala, Val, Leu, Ile, Ser o Thr; Xaa11 es: Asp, Glu, Arg, Thr, Ala, Lys o His; Xaa12 es: His, Trp, Phe o Tyr; Xaa16 es: Leu, Ser, Thr, Trp, His, Phe, Asp, Val, Tyr, Glu, o Ala; Xaa22 es: Gly, Asp, Glu, Gln, Asn, Lys, Arg, Cys o ácido cisteico; Xaa23 es: His, Asp, Lys, Glu, Gln o Arg; Xaa24 es: Glu, Arg, Ala o Lys; Xaa26 es; Trp, Tyr, Phe, Asp, Lys, Glu o His; Xaa27 es: Ala, Glu, His, Phe, Tyr, Trp, Arg o Lys; Xaa30 es: Ala, Glu, Asp, Ser o His; Xaa33 es: Asp, Arg, Val, Lys, Ala, Gly o Glu; Xaa34 es: Glu, Lys o Asp; Xaa35 es: Tbr, Ser, Lys, Arg, Trp, Tyr, Phe, Asp, Gly, Pro, His o Glu; Xaa36 es: Tbr, Ser, Asp, Trp, Tyr, Phe, Arg, Glu o His; R es: Lys, Arg, Tbr, Ser, Glu, Asp, Txp, Tyr, Phe, His, - NH2, Gly, Gly-Pro o Gly-Pro-Nh2 o no aparece. con la condición de que el compuesto GLP-1 no tenga la secuencia de GLP-1 (7-37) OH o GLP-1 (7-36) NH2 y, con tal de que el compuesto GLP-1 no sea Gly8-GLP.-1(7-37)OH, Gly8-GLP-1(7-36)NH2, Val8-GLP1-(7-37)OHM Leu8-GLP-1(7-36)NH2, Ile8-GLP-1(7-37)OH, Ile8-GLP-1(7-36NH2, Ser8- GLP-1(7-37)OH,Ser8-GLP1(7-36)NH2, Thr8-GLP-1(7-37)OH,o Thr8-GLP-1-(7-36)nh2, aLA11-glp-1(7-37)oh, aLA11-glp-1(7-36)NH2, Ala 16-GLP-1(7-37) OH, Ala16-GLP-1(7-36)NH2M ALA18-GLP-1(7-37)OH, Ala 18-GLP-1(7-36)NH2, Ala 27-GLP-1/7-37)OH, Ala27,-GLP-1(7-36)NH2, Ala33-GLP-(7-37) OH, Ala33-GLP-1(7-36NH2.A GLP-1 compound comprising the amino acid sequence of formula 1 (SEQ ID No. 1) His-Xaa8-Glu-Gly-Xaa11-Xaa12-Thr-Ser-asp-Xaa16-Ser-Ser-Tyr-Leu-Glu -Xaa22-Xaa23-Xaa24-Ala-Xaa27-Phe-Ile-Ala-Xaa31-Leu-Xaa33-Xaa34-Xaa35-Xaa36-R. Formula I (SEQ ID No: 1) in which: Xaa8 is: Gly, Ala, Val, Leu, Ile, Ser or Thr; Xaa11 is: Asp, Glu, Arg, Thr, Ala, Lys or His; Xaa12 is: His, Trp, Phe or Tyr; Xaa16 is: Leu, Ser, Thr, Trp, His, Phe, Asp, Val, Tyr, Glu, or Ala; Xaa22 is: Gly, Asp, Glu, Gln, Asn, Lys, Arg, Cys or cysteic acid; Xaa23 is: His, Asp, Lys, Glu, Gln or Arg; Xaa24 is: Glu, Arg, Ala or Lys; Xaa26 is; Trp, Tyr, Phe, Asp, Lys, Glu or His; Xaa27 is: Ala, Glu, His, Phe, Tyr, Trp, Arg or Lys; Xaa30 is: Ala, Glu, Asp, Ser or His; Xaa33 is: Asp, Arg, Val, Lys, Ala, Gly or Glu; Xaa34 is: Glu, Lys or Asp; Xaa35 is: Tbr, Ser, Lys, Arg, Trp, Tyr, Phe, Asp, Gly, Pro, His or Glu; Xaa36 is: Tbr, Ser, Asp, Trp, Tyr, Phe, Arg, Glu or His; R is: Lys, Arg, Tbr, Ser, Glu, Asp, Txp, Tyr, Phe, His, - NH2, Gly, Gly-Pro or Gly-Pro-Nh2 or does not appear. with the proviso that the GLP-1 compound does not have the sequence of GLP-1 (7-37) OH or GLP-1 (7-36) NH2 and, provided that the GLP-1 compound is not Gly8-GLP .-1 (7-37) OH, Gly8-GLP-1 (7-36) NH2, Val8-GLP1- (7-37) OHM Leu8-GLP-1 (7-36) NH2, Ile8-GLP-1 ( 7-37) OH, Ile8-GLP-1 (7-36NH2, Ser8-GLP-1 (7-37) OH, Ser8-GLP1 (7-36) NH2, Thr8-GLP-1 (7-37) OH, or Thr8-GLP-1- (7-36) nh2, aLA11-glp-1 (7-37) oh, aLA11-glp-1 (7-36) NH2, Ala 16-GLP-1 (7-37) OH , Ala16-GLP-1 (7-36) NH2M ALA18-GLP-1 (7-37) OH, Ala 18-GLP-1 (7-36) NH2, Ala 27-GLP-1 / 7-37) OH, Ala27, -GLP-1 (7-36) NH2, Ala33-GLP- (7-37) OH, Ala33-GLP-1 (7-36NH2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21217100P | 2000-06-16 | 2000-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP024392A true ECSP024392A (en) | 2003-02-06 |
Family
ID=32849305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP024392 ECSP024392A (en) | 2000-06-16 | 2002-12-13 | GLUCAGON TYPE-1 PEPTIDE ANALOGS |
Country Status (3)
| Country | Link |
|---|---|
| EC (1) | ECSP024392A (en) |
| UA (1) | UA88862C2 (en) |
| ZA (1) | ZA200210098B (en) |
-
2001
- 2001-06-01 UA UA20021210090A patent/UA88862C2/en unknown
-
2002
- 2002-12-12 ZA ZA200210098A patent/ZA200210098B/en unknown
- 2002-12-13 EC ECSP024392 patent/ECSP024392A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200210098B (en) | 2004-03-12 |
| UA88862C2 (en) | 2009-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR031701A1 (en) | COMPOUNDS ANA LOGOS OF (GLP-1) -PEPTIDE-1 GLUCAGON ANALOG, METHOD FOR STIMULATING GLP-1 RECEPTORS USING SUCH COMPOUNDS AND USING SUCH COMPOUNDS IN THE PREPARATION OF MEDICINES TO STIMULATE THE INSULIN SECRETION | |
| PE20250556A1 (en) | TRIPLE AGONIST OF GLUCAGON/GLP-1/GIP RECEPTORS | |
| AR038102A1 (en) | GLUCAGON TYPE 1 PEPTIDE EXTENDED ANALOGS | |
| PE20230861A1 (en) | LONG-ACTING GLP-1/GIP DOUBLE AGONISTS | |
| JP2008500281A5 (en) | ||
| ES2514615T3 (en) | Kunitz domain proteins calicrein inhibitors and nucleic acids encoding them | |
| JP2019504057A5 (en) | ||
| CA2320371A1 (en) | Inotropic and diuretic effects of exendin and glp-1 | |
| CA2277112C (en) | Use of exendins and agonists thereof for the reduction of food intake | |
| CA2309356A1 (en) | Novel exendin agonist compounds | |
| PE20240890A1 (en) | MODULATORS OF G PROTEIN-COUPLED RECEPTORS | |
| RU2009126634A (en) | Peptide pharmaceutical compositions and drugs on its base, method of treatment and / or prevention of diabetes or a condition associated with obesity, a method of reducing appetite, reduced food intake, a decrease in caloric intake, a decrease in body weight and increase in costs ENERGY | |
| PE20211417A1 (en) | NEW GLP-1 ANALOGS | |
| MX2021000793A (en) | Gip/glp1 co-agonist compounds. | |
| JP2009529553A5 (en) | ||
| PE20080709A1 (en) | GLUCAGON TYPE PEPTIDE 1 RECEPTOR MODULATOR POLYPEPTIDES (GLP-1) | |
| JP2014504588A5 (en) | ||
| HRP20100062T1 (en) | Glp-1 (glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance | |
| CA2048910A1 (en) | Antimicrobial peptides active against plant pathogens, their method of use and various screening methods pertaining thereto | |
| W. POTTS et al. | The effects of hypophysectomy and bovine prolactin on salt fluxes in fresh-water-adapted Fundulus heteroclitus | |
| ECSP024392A (en) | GLUCAGON TYPE-1 PEPTIDE ANALOGS | |
| AR047776A1 (en) | GLP PHARMACEUTICAL COMPOSITIONS - 1 | |
| MX2021012177A (en) | THERAPEUTIC USES OF DULAGLUTIDE. | |
| DE60306771D1 (en) | NEW PEPTIDE COMPOSITIONS AND THEIR USE, IN PARTICULAR FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS ACTING AGAINST THE HEPATITIS C VIRUS | |
| US2532798A (en) | Slingshot |